Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

News feed

Acron reports for 9 months of 2025 under IFRS

11/28/25 AKRN

ChMK reported for 9 months of 2025 according to RAS

11/28/25 CHMK

NBAMR reported for 9 months of 2025 according to RAS

11/28/25 NBAMP

Lenta will pay dividends only when higher priority goals are achieved.

11/28/25 LENT

VTB reported for 10 months of 2025 under IFRS

11/28/25 VTBR

Ministry of Finance will conduct an experiment on the sale of Russian wine on marketplaces

11/28/25 OZON

Rosseti Ural reported for 9 months of 2025 in accordance with IFRS

11/28/25 MRKU

AFK Sistema reported for 9 months of 2025 under RAS

11/27/25 AFKS

AFK Sistema reported for 9 months of 2025 under IFRS

11/27/25 AFKS

Magnit reported for 9 months of 2025 under RAS

11/27/25 MGNT